Full Library

Return to list of results

High False-Positive Rate of (1,3)-β-D-Glucan in Onco-Hematological Patients Receiving Immunoglobulins and Therapeutic Antibodies

RIS

Recommended format for most reference management software

BibTeX

Recommended format for BibTeX-specific software

Open in Zotero
View on zotero.org
Resource type
Journal Article
Authors/contributors
Title
High False-Positive Rate of (1,3)-β-D-Glucan in Onco-Hematological Patients Receiving Immunoglobulins and Therapeutic Antibodies
Abstract
Immunoglobulins and/or therapeutic antibody preparations are associated with a high rate of false-positive (1,3)-β-D-glucan (BDG) tests in onco-hematological patients routinely screened for fungal infections. The benefit of BDG monitoring shall be balanced against the risk of false-positive tests leading to unnecessary investigations and costs in this population.
Publication
Clinical Infectious Diseases
Date
2022-01-06
Pages
ciab1028
Journal Abbr
Clinical Infectious Diseases
DOI
10.1093/cid/ciab1028
URL
https://doi.org/10.1093/cid/ciab1028
Accessed
5/29/22, 5:11 PM
ISSN
1058-4838
Library Catalog
Silverchair
Citation
Tschopp, J., Brunel, A.-S., Spertini, O., Croxatto, A., Lamoth, F., & Bochud, P.-Y. (2022). High False-Positive Rate of (1,3)-β-D-Glucan in Onco-Hematological Patients Receiving Immunoglobulins and Therapeutic Antibodies. Clinical Infectious Diseases, ciab1028. https://doi.org/10.1093/cid/ciab1028
DIAGNOSTICS
Link to this record
https://www.transplantid.net/BLVZRSXQ